MedTrace Logo

Cardiac Amyloidosis : Diagnostic Using Red Flag Signals

NCT04459169 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 424

Last updated 2020-11-17

No results posted yet for this study

Summary

Cardiac amyloidosis is an increasingly contributor of degenerative cardiac diseases. However, its frequency remains underestimated, and diagnosis is often realized at late stages of the disease. A larger use of clinical and echographic Red Flag signals during routine echocardiographic examination may enhance the identification of early stage of the disease.

Conditions

  • Cardiac Amyloidosis

Interventions

PROCEDURE

diagnostic algorithm

Cardiac amyloidosis diagnosed according to Gillmore's algorithm

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University Hospital Center of Martinique

    lead OTHER

Principal Investigators

  • Doctor INAMO Jocelyn · CHU de Martinique

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-09-30
Completion
2021-12-31

Countries

  • Guadeloupe
  • Martinique

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459169 on ClinicalTrials.gov